Farther Finance Advisors’s Relmada Therapeutics RLMD Stock Holding History

Farther Finance Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$260	Buy	+69	New	+$338	﹤0.01%	5844
2026 Q2	–	Sell	-684	Closed	-$4.86K	–	6089
2026 Q1	$4.86K	Hold	684	–	–	﹤0.01%	4510
2025 Q4	$3.3K	Sell	684 -154	-18%	-$516	﹤0.01%	4495
2025 Q3	$1.68K	Buy	+838	New	+$804	﹤0.01%	4197

Other funds holding RLMD

CV Advisors Aventura, Florida $594M AUM 18% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Farther Finance Advisors's RLMD Position: Q3 2026 in Review

Farther Finance Advisors opened a new position in Relmada Therapeutics (RLMD) in Q3 2026: 69 shares worth $260. The stake represents ﹤0.01% of the portfolio and ranks #5844 among its holdings. This is a return to the name: Farther Finance Advisors previously reported a position in RLMD as recently as Q1 2026.

Farther Finance Advisors first reported a position in RLMD in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.86K in Q1 2026. 3 funds tracked by Wall St. Rank hold RLMD as of Q3 2026.

Farther Finance Advisors held 69 shares of Relmada Therapeutics worth $260 as of Q3 2026.
Relmada Therapeutics was a new Farther Finance Advisors position in Q3 2026.
Relmada Therapeutics made up ﹤0.01% of Farther Finance Advisors's portfolio in Q3 2026, its #5844 holding.
Farther Finance Advisors first reported a position in Relmada Therapeutics in Q3 2025 and has held it in 4 quarters since.
Farther Finance Advisors's Relmada Therapeutics position peaked at $4.86K in Q1 2026.
3 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2026.

Based on Farther Finance Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.